Cyrano Therapeutics has announced the initiation of the Phase 2 FLAVOR trial of CYR-064 theophylline soft-mist nasal spray in patients who have lost their sense of smell following a viral infection. Cyrano announced plans for the Phase 2 trial in January 2023. The FLAVOR trial will compare the safety and tolerability of two doses of CYR-064 to placebo over a 6-month treatment period and is expected to enroll 150 subjects.
Cyrano President and CEO Rick Geoffrion commented, “We are excited to announce a significant milestone in our commitment to advancing medical science and improving the lives of those affected by post-viral smell loss. With the enrollment of the first patients in our Phase 2 trial of CYR-064, we take a giant step forward in addressing a pressing health concern. In a world where post-viral smell loss continues to affect an ever-growing number of individuals, we’re dedicated to pioneering solutions that make a difference.”
Read the Cyrano Therapeutics press release.
